General Probiotics (GP) is a platform company that discovers, develops and commercializes a new class of antibacterial and antiviral medicines for infectious diseases.
GP designs, builds and tests advanced probiotics in an agile R&D process.
With synthetic biology techniques we engineer hundreds of variant antimicrobial probiotics. With computational biology and machine learning we can guide engineering of these live biotherapeutics, analyze the results of experiments and design new systems for high performance.
GP probiotics are tailored to eliminate pathogens effectively and reliably.
GP has been awarded Phase I/II/IIb Small Business Innovative Research grants by the US National Science Foundation and the USDA to pursue an AI-enabled, agile R&D program.